department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Aligos Therapeutics, Inc. ($ALGS) · pharmadog

PUBLIC COMPANY

$ALGSAligos Therapeutics, Inc.

South San Francisco, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

2Phase 2

Metabolic Dysfunction-Associated Steatohepatitis (MASH or…

pevifoscorvir sodium

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Aligos Therapeutics, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$ALGS

SEC CIK

0001799448

country

US

source

sec_tickers

top tags

Infectious Disease1

mentioned in

0news items

entity-linker matched

$ALGS

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 24m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Insider activity

source: SEC Form 4

routine RSU / option mechanics (4)

Mar 9, 26grantSymons Julian A. · See Remarks23,310 sh
Mar 9, 26grantAneja Nikhil · Principal Accounting Officer9,450 sh
Mar 9, 26grantCalhoun Lesley Ann · See Remarks37,485 sh
Mar 9, 26grantBLATT LAWRENCE · President and CEO105,840 sh

Active trials

phase1Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Functionrecruitingn=30
phase2A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)recruitingn=200
phase1Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Functionrecruitingn=16
phase1A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjectscompletedn=165
phase1A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Functioncompletedn=12
phase1A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Functioncompletedn=16
phase1A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulationscompletedn=8
phase1A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558completedn=90

more trials →